Wei Han

Wei Han


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
QLQian Li
Qian Li
CGCheng-Hao Guo
Cheng-Hao Guo
MCMohammed Ali Chowdhury
Mohammed Ali Chowdhury
TDTao-Li Dai
Tao-Li Dai
WHWei Han
Wei Han
Introduction: The transient receptor potential ankyrin-1 (TRPA1) channel, a pain transducer and amplifier, is drawing increasing attention in the field of visceral hypersensitivity, commonly seen in irritable bowel syndrome and inflammatory bowel disease. However, the role of TRPA1 in visceral nociception during post-inflammatory states is not well defined. Here, we explore the correlation between TRPA1 expression in the spinal dorsal horn (SDH) and persistent post-inflammatory visceral hypersensitivity. Methods: We injected rats intracolonically with 2,4,6-trinitrobenzene sulfonic acid (TNBS) or vehicle (n=12 per group). Post-inflammatory visceral hypersensitivity was assessed by recording the electromyographic activity of the external oblique muscle in response to colorectal distension. TRPA1 expression and distribution in the spinal cord and colon were examined by Western blotting and immunohistochemistry. Results: Animals exposed to TNBS had more abdominal contractions than vehicle-injected controls (P<0.05), which corresponded to a lower nociceptive threshold. Expression of TRPA1 in the SDH (especially in the substantia gelatinosa) and the colon was significantly greater in the TNBS-treated group than in controls (P<0.05). In the SDH, the number of TRPA1-immunopositive neurons was 25.75±5.12 in the control group and 34.25±7.89 in the TNBS-treated group (P=0.023), and integrated optical density values of TRPA1 in the control and TNBS-treated groups were 14,544.63±6,525.54 and 22,532.75±7,608.11, respectively (P=0.041). Conclusion: Our results indicate that upregulation of TRPA1 expression in the SDH is associated with persistent post-inflammatory visceral hypersensitivity in the rat and provides insight into potential therapeutic targets for the control of persistent visceral hypersensitivity.

3 January 2025 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
LCLina Cao
Lina Cao
GLGaozhong Li
Gaozhong Li
JCJingmei Cao
Jingmei Cao
FLFuxin Li
Fuxin Li
WHWei Han
Wei Han
Background: Functional dyspepsia (FD) is one of the most common gastrointestinal disorders worldwide. Currently, anti-gastric drugs, gastric acid inhibitors, prokinetic drugs, and mucosal protective drugs are widely used in FD patients, however, only a small proportion of patients benefit from these drugs. Studies reported mirtazapine may improve symptoms of FD patients but the efficacy and safety of mirtazapine in the treatment of FD is unclear. Objectives: To investigate the efficacy and safety of mirtazapine in FD patients. Design: We performed a prospective, single-randomized, two-group parallel clinical trial involving 120 FD patients with poor traditional drug treatment outcomes to evaluate the efficacy and safety of mirtazapine. Methods: Qualified patients identified through the screening assessments were randomly divided into two groups: mirtazapine group ( n = 60) treated with mirtazapine 15 mg qn on top of traditional drugs, and control group ( n = 60) who continued to be treated with traditional drugs. Subjects were evaluated for meal-related symptoms and severity, quality of life, gastrointestinal-specific anxiety, and body weight before and after the 8-week intervention. Adverse reactions were also recorded. Results: At the end of 8-week treatment, dyspeptic symptoms in the mirtazapine group were significantly relieved compared with the baseline (7.95 ± 1.86 vs 11.17 ± 2.14, p < 0.001). Assessment of the impact of dyspepsia on patients’ quality of life from the short form-Nepean Dyspepsia Index showed that patients generally feel better in mirtazapine group than control group (24.52 ± 2.87 vs 28.64 ± 4.32, p < 0.001). Mirtazapine group also showed significant weight gain and decreased visceral sensitivity index score. Conclusion: Compared with control group, 8-week administration of mirtazapine significantly improved the overall severity of symptoms of dyspepsia (such as individual symptoms of postprandial fullness, early satiation, nausea, and vomiting), gastrointestinal-specific anxiety, quality of life, and increased weight in FD patients. This study provided clues to clinicians that mirtazapine may be a good choice for the treatment of FD patients. Trial registration: This study was registered in the Chinese clinical trial registry ( https://www.chictr.org.cn/index.html , protocol No. ChiCTR2100048304).

1 May 2013 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
XMXiao-Dong Mo
Xiao-Dong Mo
LXLan-Ping Xu
Lan-Ping Xu
DLDai-hong Liu
Dai-hong Liu
XZXiao-hui Zhang
Xiao-hui Zhang
HCHuan Chen
Huan Chen
Xiaojun HuangXiaojun Huang
Xiaojun Huang
Human leukocyte antigen (HLA) partially matched related donor (PMRD) hematopoietic stem cell transplantation (HSCT) is an effective option for hematological malignancies. In this study, the nonmalignant late effects of PMRD HSCT were evaluated and compared with HLA-identical sibling donor (ISD) HSCT. Three hundred thirteen patients (ISD, n = 160; PMRD, n = 153) who survived at least 6 months and received regular follow-up examinations after their HSCT were enrolled. The 5-year cumulative incidence (±SE) of at least one late effect and multiple late effects was 47.30% ± .17% versus 58.21% ± .16% (P = .134) and 17.97% ± .10% versus 34.28% ± .15% (P = .001) for PMRD HSCT recipients versus ISD HSCT recipients, respectively. The cumulative incidence of keratoconjunctivitis sicca, periodontitis, ankylosis, myalgia, and nephrotic syndrome was lower among PMRD HSCT recipients compared with ISD HSCT recipients. Severe chronic graft-versus-host disease, multiple pre-HSCT chemotherapy cycles, female donor, and older age were risk factors for at least one late effect. Female donor, older age, and long-term immunosuppressive therapy were associated with multiple late effects. In summary, PMRD HSCT recipients have a lower risk of late effects compared with ISD HSCT recipients, possibly due to differences in protocols for graft-versus-host disease prophylaxis, and long-term follow-up after transplantation is recommended.


12 March 2018 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
XMXiao-Dong Mo
Xiao-Dong Mo
XZXiao-hui Zhang
Xiao-hui Zhang
LXLan-Ping Xu
Lan-Ping Xu
YWYu Wang
Yu Wang
CYChen-Hua Yan
Chen-Hua Yan
Xiaojun HuangXiaojun Huang
Xiaojun Huang
We aimed to evaluate the treatments, particularly the role of corticosteroids, in patients with late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). One hundred and sixty-three consecutive patients who underwent non-T-cell-depleted allo-HSCT and met the criterion of LOHC after allo-HSCT were enrolled in this study. The median time from allo-HSCT to the occurrence of LOHC was 29 (range, 4–155) days. Pathogens identified in blood and/or urine samples from 143 patients were mostly viruses. All of the patients with LOHC received intravenous fluid hydration, alkalization, and forced diuresis, of which 2 patients achieved complete remission (CR) after these treatments. The remaining 161 patients received anti-infection therapies and 71 achieved CR after the therapies. Corticosteroids were additionally applied to 83 out of 90 patients who did not achieve CR after anti-infection therapies, and 88.0% (n = 73) of them showed a grade 3 to 4 LOHC at the beginning of corticosteroid therapy. Thirty-five patients showed an immediate response (CR or downgraded at least one grade) within 1 week after the beginning of the corticosteroid therapy. Sixty-four patients (77.1%) achieved CR after corticosteroid therapy, and the median period from the beginning of corticosteroid therapy to CR was 17 days. Thus, we observed that viruses were the most common pathogens in LOHC after allo-HSCT and that anti-infection therapies were critical. For patients not showing a satisfactory response to anti-infection therapies, additional corticosteroid therapy may help to achieve CR.

30 June 2021 in International Journal of Fluid Machinery and Systems
Verified
Journal Article
Closed access
XZXuejing Zhang
Xuejing Zhang
JYJunhu Yang
Junhu Yang
WBWenkai Bei
Wenkai Bei
WHWei Han
Wei Han
CCCanyang Chen
Canyang Chen
LYLe Yang
Le Yang
The efficiency of multiphase twin-screw pump decreases sharply under wet gas conditions (GVF>95%) with severe vibration and thermal problems. Based on the design characteristics of twin-screw pump and screw compressor, a design method of multigradient variable pitch decompression screw pump is to address these problems in this paper. This method keeps the cross section profiles of screw pump unchanged,only changes the pitch of screw. According to the design concept of decompression of screw compressor, the screw rotor is divided into three regions from the inlet to the outlet. The pitch of screw and thread width in these regions are designed separately to increase the volumetric efficiency of the screw pump and reduce the vibration. The effective clearance leakage model of twin-screw pump is simplified and modified. Considering two-phase back flow and combining mechanical model with thermodynamic model, the flow capacity, volumetric efficiency, pressure, and temperature distribution of new and conventional screw pumps are predicted by non-isothermal compression model. The calculations show that the design scheme of multi-gradient variable-pitch decompression screw pump can solve the volumetric efficiency and vibration problems under wet gas conditions fundamentally and can significantly reduce the power consumption of screw pump. However, the problem of temperature rise of screw pump still exists. Cooling system for the screw pump should be designed to continuously cool the screw pump.